Cargando…

Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

SIMPLE SUMMARY: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative option for high-risk hematologic malignancies. However, disease recurrence after allo-HSCT remains a critical issue, underlining the need to develop maintenance therapy. In this context, NK cell-based immuno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Devillier, Raynier, Calmels, Boris, Guia, Sophie, Taha, Mohammed, Fauriat, Cyril, Mfarrej, Bechara, Venton, Geoffroy, Vivier, Eric, Olive, Daniel, Chabannon, Christian, Blaise, Didier, Ugolini, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198961/ https://www.ncbi.nlm.nih.gov/pubmed/34071607 http://dx.doi.org/10.3390/cancers13112673

Ejemplares similares

Manufacturing Natural Killer Cells as Medicinal Products
por: Chabannon, Christian, et al.
Publicado: (2016)

Impact of Pretransplant Donor and Recipient Cytomegalovirus Serostatus on Outcome for Multiple Myeloma Patients Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation
por: El-Cheikh, Jean, et al.
Publicado: (2013)

Sepax-2 cell processing device: a study assessing reproducibility of concentrating thawed hematopoietic progenitor cells
por: Mfarrej, Bechara, et al.
Publicado: (2022)

Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity
por: Chretien, Anne-Sophie, et al.
Publicado: (2014)

Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome
por: Castagna, Luca, et al.
Publicado: (2020)

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML
por: Chretien, Anne-Sophie, et al.
Publicado: (2017)

Related versus unrelated allogeneic HPC graft cryopreservation: a single-center experience in the context of the global COVID-19 pandemic
por: Mfarrej, B., et al.
Publicado: (2021)

Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia
por: Chretien, Anne-Sophie, et al.
Publicado: (2015)

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors
por: Cruz, David, et al.
Publicado: (2023)

Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients
por: Castagna, Luca, et al.
Publicado: (2020)

High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome
por: Chretien, Anne-Sophie, et al.
Publicado: (2021)

Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Host resistance to endotoxic shock requires the neuroendocrine regulation of group 1 innate lymphoid cells
por: Quatrini, Linda, et al.
Publicado: (2017)

Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysis
por: Gao, Wen-hui, et al.
Publicado: (2023)

Harnessing allogeneic NK cells: improving outcomes with tailored donor lymphocyte infusion
por: McCurdy, Shannon R.
Publicado: (2022)

Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression
por: Mfarrej, Bechara, et al.
Publicado: (2017)

Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity
por: Bernard, Pierre-Louis, et al.
Publicado: (2022)

Natural Killer Cells: From Basic Research to Treatments
por: Vivier, Eric, et al.
Publicado: (2011)

Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients
por: Impola, Ulla, et al.
Publicado: (2014)

Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells
por: Quatrini, Linda, et al.
Publicado: (2018)

Days Alive Outside Hospital and Readmissions in Patients Undergoing Allogeneic Transplants from Identical Siblings or Alternative Donors
por: Sora, Federica, et al.
Publicado: (2020)

Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study
por: Ruggeri, Annalisa, et al.
Publicado: (2016)

Autoimmune hematological diseases following haploidentical donor hematopoietic stem cell transplant compared with matched sibling and unrelated donor
por: Lv, Weiran, et al.
Publicado: (2017)

The kinetics of HTLV-1 proviral load after allogeneic hematopoietic cell transplantation with reduced intensity conditioning regimen; a comparison with that from sibling donors and that from unrelated donors
por: Choi, Ilseung, et al.
Publicado: (2014)

Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/VLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF
por: Garciaz, Sylvain, et al.
Publicado: (2020)

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
por: Schmid, Christoph, et al.
Publicado: (2021)

Data mining of mental health issues of non-bone marrow donor siblings
por: Takita, Morihito, et al.
Publicado: (2011)

Co-designing genomics research with a large group of donor-conceived siblings
por: Nunn, Jack S., et al.
Publicado: (2021)

T cell regulation of natural killer cells
por: Kerdiles, Yann, et al.
Publicado: (2013)

Neuroendocrine regulation of innate lymphoid cells
por: Quatrini, Linda, et al.
Publicado: (2018)

Selection of Suitable Alternative Donor in the Absence of Matched Sibling Donor: A Retrospective Single-Center Study to Compare between Haploidentical, 10/10 and 9/10 Unrelated Donor Transplantation
por: Barkhordar, Maryam, et al.
Publicado: (2021)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Donor Selection and Prophylactic Strategy for Venous Thromboembolic Events in Living Donors of Liver Transplantation Based on Results of Thrombophilia Screening Tests
por: Kamei, Hideya, et al.
Publicado: (2017)

Prospective cohort study of the circadian rhythm pattern in allogeneic sibling donors undergoing standard granulocyte colony-stimulating factor mobilization
por: Shi, Patricia A, et al.
Publicado: (2013)

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
por: Brissot, Eolia, et al.
Publicado: (2017)

P33. NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells
por: Klingemann, H
Publicado: (2014)

Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation
por: Morin-Zorman, Sarah, et al.
Publicado: (2016)

Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study
por: Chang, Ying-Jun, et al.
Publicado: (2020)

Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia
por: Zhang, Yuanfeng, et al.
Publicado: (2022)

A Prospective Trial Comparing Haploidentical Donor Transplantation With Cord Blood Versus HLA-Matched Sibling Donor Transplantation for Hematologic Malignancy Patients
por: Lu, Wenyi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ekcpr9khbaleje3enhpuhjkhfb